Votrient Maintenance Therapy Fails to Improve Survival in Advanced Ovarian Cancer Patients, Trial Results Show

Votrient Maintenance Therapy Fails to Improve Survival in Advanced Ovarian Cancer Patients, Trial Results Show
Maintenance treatment with Votrient (pazopanib) does not extend the survival of newly diagnosed advanced ovarian cancer patients whose disease did not worsen after surgery and first-line chemotherapy, according to Phase 3 trial data. However, the approach extended the time until disease worsening or death — as shown in a prior analysis — which delayed the need for additional cancer therapies. The findings are being presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, June 1-5 in Chicago, in a poster titled “AGO-OVAR 16: A phase III study to evaluate the efficacy and safety of pazopanib (PZ) monotherapy versus placebo in women who have not progressed after first line chemotherapy for epithelial ovarian, fallopian tube, or primary peritoneal cancer—Overall survival (OS) results.” Votrient, by Novartis, is an inhibitor of tyrosine kinase proteins, including VEGFR-1, -2, -3, PDGFR-α and -β, and c-Kit. These proteins are known to promote cancer cell survival and proliferation. The medicine is approved for the treatment of advanced renal cell carcinoma and soft tissue sarcoma. The AGO-OVAR 16 Phase 3 trial (NCT00866697) was designed to determine if Votrient could safely delay disease worsening or death in women with advanced ovarian cancer whose cancer has not progressed after firs
Subscribe or to access all post and page content.